Inherited disorders as a risk factor and predictor of neurodevelopmental outcome in pediatric cancer

Developmental Disabilities Research Reviews

Volumn 14, Issue 3, 2008, Pages 229-237

  Ullrich, Nicole J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cancer; Children; Cognition; Genetic susceptibility; Headache; Late effects; Neuropathy; Seizures

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; APC PROTEIN; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MERLIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN PATCHED; PROTEIN RET; RAPAMYCIN; TRANSCRIPTION FACTOR SNF; TRANSCRIPTION FACTOR SNF5; TUBERIN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN;

ACUTE LYMPHOCYTIC LEUKEMIA; APC GENE; ASTROCYTOMA; ATAXIA TELANGIECTASIA; AUTOSOMAL DOMINANT INHERITANCE; BASAL CELL NEVUS SYNDROME; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SUSCEPTIBILITY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD CARE; CHILDHOOD CANCER; CHROMOSOME ABERRATION; CLINICAL FEATURE; COWDEN SYNDROME; DISEASE ASSOCIATION; DRUG MECHANISM; FAMILIAL CANCER; FAMILIAL DISEASE; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; MEDULLOBLASTOMA; MOYAMOYA DISEASE; NERVOUS SYSTEM DEVELOPMENT; NEURILEMOMA; NEUROFIBROMATOSIS; NEUROLOGICAL COMPLICATION; NF1 GENE; NF2 GENE; NONHUMAN; OPTIC NERVE GLIOMA; OUTCOME ASSESSMENT; PLEXIFORM NEUROFIBROMA; PRIORITY JOURNAL; PTCH GENE; RADIATION DOSE; RADIATION INJURY; REVIEW; RISK FACTOR; SKIN TUMOR; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TP53 GENE; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE; TURCOT SYNDROME; VON HIPPEL LINDAU DISEASE;

EID: 55449115841     PISSN: 19405510     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/ddrr.30     Document Type: Review

References (77)

1. Abel TW, Baker SJ, Fraser MM, et al. 2005. Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol 64:341-349.
2. Armstrong CL, Hunter JV, Ledakis GE, et al. 2002. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 59:40-48.
3. Baser ME, Evans DG, Jackler RK, et al. 2000. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 82:998.
4. Bhat SR, Goodwin TL, Burwinkle TM, et al. 2005. Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol 23:5493-5500.
5. Broniscer A, Ke W, Fuller CE, et al. 2004. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer 100:2246-2252.
6. Butler RW, Haser JK. 2006. Neurocognitive effects of treatment for childhood cancer. Ment Retard Dev Disabil Res Rev 12:184-191.
7. Chao RC, Pyzel U, Fridlyand J, et al. 2005. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell 8:337-348.
8. Costa RM, Silva AJ. 2002. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1. J Child Neurol 17:622-626; discussion 627-629:646-651.
9. Coude FX, Mignot C, Lyonnet S, et al. 2006. Academic impairment is the most frequent complication of neurofibromatosis type-1 (NF1) in children. Behav Genet 36:1-5.
10. Cross NE, Glantz MJ. 2003. Neurologic complications of radiation therapy. Neurol Clin 21:249-277.
11. Cutting LE, Koth CW, Denckla MB. 2000. How children with neurofibromatosis type 1 differ from "typical" learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 17:29-47.
12. Danoff BF, Cowchock FS, Marquette C, et al. 1982. Assessment of the long-term effects of primary radiation therapy for brain tumors in children. Cancer 49:1580-1586.
13. Duffner PK. 2004. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 10:293-310.
14. Duffner PK, Horowitz ME, Krischer JP, et al. 1993. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328:1725-1731.
15. Evans DG. 1999. Neurofibromatosis type 2: genetic and clinical features. Ear Nose Throat J 78:97-100.
16. Evans DG, Baser ME, O'Reilly B, et al. 2005. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19:5-12.
17. Evans DG, Birch JM, Ramsden RT, et al. 2006. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 43:289-294.
18. Evans DG, Farndon PA, Burnell LD, et al. 1991. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 64:959-961.
19. Farndon PA, Del Mastro RG, Evans DG, et al. 1992. Location of gene for Gorlin syndrome. Lancet 339:581-582.
20. Ferner RE. 2007. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 6:340-351.
21. Fletcher JM, Copeland DR. 1988. Neurobehavioral effects of central nervous system prophylactic treatment of cancer in children. J Clin Exp Neuropsychol 10:495-537.
22. Franz DN, Leonard J, Tudor C, et al. 2006. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490-498.
23. Hofman KJ, Harris EL, Bryan RN, et al. 1994. Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 124:S1-S8.
24. Horn P, Pfister S, Bueltmann E, et al. 2004. Moyamoya-like vasculopathy (moyamoya syndrome) in children. Childs Nerv Syst 20:382-391.
25. Hyman MH, Whittemore VH. 2000. National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 57:662-665.
26. Hyman SL, Shores A, North KN. 2005. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037-1044.
27. Imhof SM, Moll AC, Schouten-van Meeteren AY. 2006. Stage of presentation and visual outcome of patients screened for familial retinoblastoma: nationwide registration in the Netherlands. Br J Ophthalmol 90:875-878.
28. Jawahar A, Kondziolka D, Garces YI, et al. 2000. Stereotactic radiosurgery for hemangioblastomas of the brain. Acta Neurochir (Wien) 142:641-644; discussion 644-645.
29. Joinson C, O'Callaghan FJ, Osborne JP, et al. 2003. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 33:335-344.
30. Kaelin WG. 2007. Von Hippel-Lindau disease. Annu Rev Pathol 2:145-173.
31. Kim WY, Kaelin WG. 2004. Role of VHL gene mutation in human cancer. J Clin Oncol 22:4991-5004.
32. King TZ, Fennell EB, Williams L, et al. 2004. Verbal memory abilities of children with brain tumors. Child Neuropsychol 10:76-88.
33. Koth CW, Cutting LE, Denckla MB. 2000. The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol 6:185-194.
34. Latif F, Tory K, Gnarra J, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320.
35. Li C, Cheng Y, Gutmann DA, et al. 2001. Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. Brain Res Dev Brain Res 130:231-248.
36. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. 1988. A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362.
37. Limacher JM, Frebourg T, Natarajan-Ame S, et al. 2001. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96:238-242.
38. Listernick R, Louis DN, Packer RJ, et al. 1997. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41:143-149.
39. Maddrey AM, Bergeron JA, Lombardo ER, et al. 2005. Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma. J Neurooncol 72:245-253.
40. Mahgoub N, Taylor BR, Le Beau MM, et al. 1999. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood 93:3617-3623.
41. Mathieu D, Kondziolka D, Flickinger JC, et al. 2007. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60:460-468; discussion 468-470.
42. Mautner VF, Tatagiba M, Guthoff R, et al. 1993. Neurofibromatosis 2 in the pediatric age group. Neurosurgery 33:92-96.
43. McClatchey AI, Giovannini M. 2005. Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev 19:2265-2277.
44. McKinnon PJ. 2004. ATM and ataxia telangiectasia. EMBO Rep 5:772-776.
45. Merchant TE, Kiehna EN, Miles MA, et al. 2002. Acute effects of irradiation on cognition: changes in attention on a computerized continuous performance test during radiotherapy in pediatric patients with localized primary brain tumors. Int J Radiat Oncol Biol Phys 53:1271-1278.
46. Mitchell WG, Fishman LS, Miller JH, et al. 1991. Stroke as a late sequela of cranial irradiation for childhood brain tumors. J Child Neurol 6:128-133.
47. Morrell D, Chase CL, Swift M. 1990. Cancers in 44 families with ataxia-telangiectasia. Cancer Genet Cytogenet 50:119-123.
48. Motzer RJ, Bukowski RM. 2006. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601-5608.
49. Mulhern RK, Butler RW. 2004. Neurocognitive sequelae of childhood cancers and their treatment. Pediatr Rehabil 7:1-14; discussion 15-16.
50. Nelen MR, Kremer H, Konings IB, et al. 1999. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 7:267-273.
51. Nutting C, Camplejohn RS, Gilchrist R, et al. 2000. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 12:300-304.
52. O'Callaghan FJ, Harris T, Joinson C, et al. 2004. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child 89:530-533.
53. Olivier M, Goldgar DE, Sodha N, et al. 2003. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643-6650.
54. Packer RJ, Meadows AT, Rorke LB, et al. 1987. Long-term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol 15:241-253.
55. Pan L, Wang EM, Wang BJ, et al. 1998. Gamma knife radiosurgery for hemangioblastomas. Stereotact Funct Neurosurg 70(Suppl 1):179-186.
56. Raja D, Benz MS, Murray TG, et al. 2004. Salvage external beam radiotherapy of retinal capillary hemangiomas secondary to von Hippel-Lindau disease: visual and anatomic outcomes. Ophthalmol 111:150-153.
57. Renwick A, Thompson D, Seal S, et al. 2006. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38:873-875.
58. Ris MD, Packer R, Goldwein J, et al. 2001. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 19:3470-3476.
59. Romer JT, Kimura H, Magdaleno S, et al. 2004. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 6:229-240.
60. Rosser T, Packer RJ. 2002. Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol 17:630-637; discussion 646-651.
61. Rouleau GA, Merel P, Lutchman M, et al. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515-521.
62. Rowe J, Grainger A, Walton L, et al. 2007. Safety of radiosurgery applied to conditions with abnormal tumor suppressor genes. Neurosurgery 60:860-864; discussion 860-864.
63. Schatz J, Kramer JH, Ablin A, et al. 2000. Processing speed, working memory, and IQ: a developmental model of cognitive deficits following cranial radiation therapy. Neuropsychology 14:189-200.
64. Schrimsher GW, Billingsley RL, Slopis JM, et al. 2003. Visual-spatial performance deficits in children with neurofibromatosis type-1. Am J Med Genet A 120:326-330.
65. Shanley S, Ratcliffe J, Hockey A, et al. 1994. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet 50:282-290.
66. Sharif S, Ferner R, Birch JM, et al. 2006. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24:2570-2575.
67. Shen MH, Harper PS, Upadhyaya M. 1996. Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet 33:2-17.
68. Strahm B, Malkin D. 2006. Hereditary cancer predisposition in children: genetic basis and clinical implications. Int J Cancer 119:2001-2006.
69. Szeimies RM, Karrer S. 2006. Towards a more specific therapy: targeting nonmelanoma skin cancer cells. Br J Dermatol 154(Suppl 1):16-21.
70. Tee AR, Fingar DC, Manning BD, et al. 2002. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99:13571-13576.
71. Thomas GV, Tran C, Mellinghoff IK, et al. 2006. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127.
72. Trofatter JA, MacCollin MM, Rutter JL, et al. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800.
73. Ullrich NJ, Raja AI, Irons MB, et al. 2007a. Brainstem lesions in neurofibromatosis type 1. Neurosurgery 61:762-766; discussion 766-767.
74. Ullrich NJ, Robertson R, Kinnamon DD, et al. 2007b. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 68:932-938.
75. Verma S, Tavare C, Gilles F. 2008. Histologic features and prognosis in pediatric medulloblastoma. Pediatr Dev Pathol:1.
76. Weiss B, Bollag G, Shannon K. 1999. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 89:14-22.
77. Winterkorn EB, Pulsifer MB, Thiele EA. 2007. Cognitive prognosis of patients with tuberous sclerosis complex. Neurology 68:62-64.